Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
0.3901
-0.0183 (-4.48%)
Mar 31, 2025, 2:19 PM EDT - Market open
Company Description
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.
The company’s lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia.
Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Acurx Pharmaceuticals, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Jun 25, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | David Luci |
Contact Details
Address: 259 Liberty Avenue Staten Island, New York 10305 United States | |
| Phone | 917 533 1469 |
| Website | acurxpharma.com |
Stock Details
| Ticker Symbol | ACXP |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $6.00 |
| CIK Code | 0001736243 |
| CUSIP Number | 00510M104 |
| ISIN Number | US00510M1045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Robert J. DeLuccia | Co-Founder and Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 28, 2025 | 8-K | Current Report |
| Mar 21, 2025 | D | Notice of Exempt Offering of Securities |
| Mar 19, 2025 | EFFECT | Notice of Effectiveness |
| Mar 18, 2025 | 8-K | Current Report |
| Mar 17, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 17, 2025 | POS AM | Post-Effective amendments for registration statement |
| Mar 17, 2025 | 10-K | Annual Report |
| Mar 10, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 424B5 | Filing |
| Feb 26, 2025 | 8-K | Current Report |